We tested the effect of GLUT3 inhibitors on the cell viability of several different cancer lines: myeloid leukemia (HL60 and U937), lung cancer (A549), colorectal adenocarcinoma (Caco-2), breast cancer (MCF7), hepatocellular carcinoma (HepG2), and choriocarcinoma (BeWo) cells. Here, SLC2A3 is linked to hepatocellular carcinoma.